Saturday 17 October 2026
Export NCEL’s income statement to Excel — free account
NewcelX Ltd.
NCEL Healthcare Biotechnology
Insiders bought in the last twelve months.
2.50
0.35
−12.28%
Follow NCEL
NewcelX Ltd. (NCEL) P/E ratio
NewcelX Ltd. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 0.0× (October 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| DARE Dare Bioscience, Inc. compare | n/m |
| GTBP GT Biopharma, Inc. compare | n/m |
| MRKR MARKER THERAPEUTICS, INC. compare | n/m |
| TCRX TScan Therapeutics, Inc. compare | n/m |
| AKTX Akari Therapeutics PLC compare | n/m |
| NCEL NewcelX Ltd. | n/m |
| ADAPY Adaptimmune Therapeutics PLC compare | n/m |
| VAXX Vaxxinity, Inc. compare | n/m |
| PBM Psyence Biomedical Ltd. compare | 0.2× |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)